Immune Globulin Thrombotic Class Labeling Precaution Requested By FDA
Executive Summary
Intravenous immune globulin manufacturers have until Jan. 14 to include a precaution in product labeling on thrombotic events, FDA says in a 1letter to manufacturers posted on the agency's website Dec. 15
You may also be interested in...
ZLB Rhophylac clears FDA
ZLB Bioplasma will make its IGIV product Rhophylac available in the U.S. in March, the company says. FDA approved Rhophylac for the prevention of hemolytic disease of the fetus and newborn Feb. 17. Rhophylac is the first U.S.-approved liquid Rh immune globulin product that can be administered either intravenously or intramuscularly, ZLB said. Rhophylac labeling does not include a precaution about an association between IGIV products and thrombotic events as requested by FDA for all IGIV products (1"The Pink Sheet" Jan. 5, 2004, p. 18)...
ZLB Rhophylac clears FDA
ZLB Bioplasma will make its IGIV product Rhophylac available in the U.S. in March, the company says. FDA approved Rhophylac for the prevention of hemolytic disease of the fetus and newborn Feb. 17. Rhophylac is the first U.S.-approved liquid Rh immune globulin product that can be administered either intravenously or intramuscularly, ZLB said. Rhophylac labeling does not include a precaution about an association between IGIV products and thrombotic events as requested by FDA for all IGIV products (1"The Pink Sheet" Jan. 5, 2004, p. 18)...
IGIV Manufacturer Letters Should Be Ignored During FDA Review, Agency Says
Prescriber letters sent by immune globulin intravenous manufacturers asserting superiority over other IGIV products should be disregarded while FDA completes its safety review of thrombotic events, the agency said